NO985464L - Konsentrert antistoffpreparat - Google Patents

Konsentrert antistoffpreparat

Info

Publication number
NO985464L
NO985464L NO985464A NO985464A NO985464L NO 985464 L NO985464 L NO 985464L NO 985464 A NO985464 A NO 985464A NO 985464 A NO985464 A NO 985464A NO 985464 L NO985464 L NO 985464L
Authority
NO
Norway
Prior art keywords
antibody preparation
concentrated antibody
preparation
concentrated
disclosed
Prior art date
Application number
NO985464A
Other languages
English (en)
Other versions
NO985464D0 (no
Inventor
Julian Marcus Relton
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO985464(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO985464D0 publication Critical patent/NO985464D0/no
Publication of NO985464L publication Critical patent/NO985464L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives et konsentrert antistoffpreparat, farmasøytiske formuleringer inneholdende et slikt preparat, dets anvendelse i human terapi og fremgangsmåter for dets fremstilling.
NO985464A 1996-05-24 1998-11-23 Konsentrert antistoffpreparat NO985464L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9610992.1A GB9610992D0 (en) 1996-05-24 1996-05-24 Concentrated antibody preparation
PCT/EP1997/002595 WO1997045140A1 (en) 1996-05-24 1997-05-22 Concentrated antibody preparation

Publications (2)

Publication Number Publication Date
NO985464D0 NO985464D0 (no) 1998-11-23
NO985464L true NO985464L (no) 1999-01-18

Family

ID=10794316

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985464A NO985464L (no) 1996-05-24 1998-11-23 Konsentrert antistoffpreparat

Country Status (28)

Country Link
US (1) US6252055B1 (no)
EP (1) EP0907378B1 (no)
JP (1) JP3338060B2 (no)
KR (1) KR20000015935A (no)
CN (1) CN1219882A (no)
AP (1) AP9801392A0 (no)
AR (1) AR007249A1 (no)
AT (1) ATE318146T1 (no)
AU (1) AU731950B2 (no)
BR (1) BR9709267A (no)
CA (1) CA2254983A1 (no)
CO (1) CO4850562A1 (no)
CZ (1) CZ382498A3 (no)
DE (1) DE69735295T2 (no)
EA (1) EA001860B1 (no)
ES (1) ES2258277T3 (no)
GB (1) GB9610992D0 (no)
ID (1) ID16966A (no)
IL (1) IL126940A0 (no)
IS (1) IS4892A (no)
NO (1) NO985464L (no)
NZ (1) NZ332625A (no)
PE (1) PE69098A1 (no)
PL (1) PL330111A1 (no)
TR (1) TR199802423T2 (no)
WO (1) WO1997045140A1 (no)
YU (1) YU53098A (no)
ZA (1) ZA974486B (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2371427A1 (en) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
JP4812228B2 (ja) * 2000-08-10 2011-11-09 中外製薬株式会社 抗体含有溶液の凝集物生成または白濁抑制方法
EP2116265B1 (en) * 2000-10-12 2020-12-23 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6365395B1 (en) * 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AU2006202688B2 (en) * 2001-05-31 2009-01-22 Genentech, Inc. Stable liquid formulations of antibodies
CA2868614A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
AU2002342151B2 (en) * 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
AU2003212912A1 (en) 2002-02-04 2003-09-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CN101066450A (zh) 2002-02-14 2007-11-07 中外制药株式会社 包含抗体的溶液制剂
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2490423A1 (en) * 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2012202845B2 (en) * 2003-02-10 2014-09-04 Biogen Ma Inc. Immunoglobulin formulation and method of preparation thereof
PT3417875T (pt) 2003-02-10 2020-08-24 Biogen Ma Inc Formulação de imunoglobulinas e método de preparação das mesmas
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US20070172475A1 (en) * 2004-02-12 2007-07-26 Susanne Matheus Highly concentrated, liquid formulations of anti-egfr antibodies
WO2005086698A2 (en) * 2004-03-04 2005-09-22 Mayo Foundation For Medical Education And Research Methods for altering t cell diversity
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CA2566075A1 (en) * 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
DK1758558T3 (da) 2004-05-12 2014-01-20 Baxter Int Oligonukleotidholdige mikrokugler samt deres anvendelse til fremstilling af et medikament til behandling af diabetes type 1
ES2422757T3 (es) 2004-05-12 2013-09-13 Baxter Int Uso terapéutico de microesferas de ácido nucleico
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP1858552A2 (en) 2005-03-08 2007-11-28 Pharmacia & Upjohn Company LLC Composition comprising human igg2 antibody and a chelating agent
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
CA2893252C (en) 2005-08-24 2018-05-29 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
SI1942939T2 (sl) * 2005-09-30 2021-11-30 Medimmune Limited Sestavek protitelesa proti interlevkinu-13
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
BRPI0709726A2 (pt) 2006-04-05 2011-07-26 Abbott Biotechnology Ltd. purificaÇço de anticorpo
WO2008019346A2 (en) 2006-08-04 2008-02-14 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
JP5744513B2 (ja) 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
JP2010532790A (ja) * 2007-07-06 2010-10-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方
US8633302B2 (en) 2007-07-17 2014-01-21 Hoffmann-La Roche Inc. Variable tangential flow filtration
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20100249384A1 (en) * 2007-11-29 2010-09-30 Stefan Hepbildikler Immunoglobulin aggregates
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
BRPI0821600A2 (pt) * 2007-12-28 2015-06-23 Bioinvent Int Ab Composição farmacêutica, artigo de fabricação, kit de partes, método de combater aterosclerose, ou uma doença cardiovascular associada à aterosclerose, e, uso de um anticorpo
AU2009236305B2 (en) 2008-04-15 2014-04-10 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
JP6159528B2 (ja) * 2009-03-24 2017-07-05 ワイス・エルエルシー 高濃縮のタンパク質治療薬を生成するための膜蒸発
JP2012526121A (ja) * 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
CN105001335B (zh) 2010-03-01 2019-10-25 拜耳医药保健有限公司 针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体
PT2616090T (pt) 2010-09-17 2023-10-16 Takeda Pharmaceuticals Co Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro
EP2637690B1 (en) 2010-11-11 2016-09-21 AbbVie Biotechnology Ltd HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
CN107115526A (zh) * 2011-05-02 2017-09-01 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
TWI610937B (zh) 2011-08-26 2018-01-11 巴克斯歐塔公司 用於降低血漿來源免疫球蛋白組成物之血栓性栓塞可能性的方法
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
DK2892550T3 (da) 2012-09-07 2020-03-30 Coherus Biosciences Inc Stabile vandige formuleringer af adalimumab
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
EP2727643A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Cross-flow ultrafiltration device and method for concentration of pharmaceutical compositions
CN111202711B (zh) 2013-09-11 2022-06-21 伊戈尔生物药品股份有限公司 包含有机磷酸酯的液体蛋白质制剂
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
WO2015157286A1 (en) * 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
WO2015168622A1 (en) * 2014-05-01 2015-11-05 Virginia Tech Intellectual Properties, Inc. Keratin nanomaterials and methods of production
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
JP7483679B2 (ja) * 2018-08-14 2024-05-15 ブリストル－マイヤーズ スクイブ カンパニー 改善されたタンパク質の回収

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064210B2 (en) 1981-05-01 1991-03-06 Miles Inc. Oral pharmaceutical composition containing immune globulin
JPH01268646A (ja) * 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
CH684164A5 (de) 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.
DE4211169C1 (no) * 1992-03-31 1993-06-03 Klaus Kretzschmar
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
WO1994015640A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
PT2275119E (pt) * 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável

Also Published As

Publication number Publication date
JP3338060B2 (ja) 2002-10-28
ZA974486B (en) 1998-11-23
WO1997045140A1 (en) 1997-12-04
NZ332625A (en) 2000-04-28
AU731950B2 (en) 2001-04-05
BR9709267A (pt) 1999-08-10
US6252055B1 (en) 2001-06-26
JPH11512753A (ja) 1999-11-02
NO985464D0 (no) 1998-11-23
AP9801392A0 (en) 1998-12-31
CZ382498A3 (cs) 1999-05-12
AR007249A1 (es) 1999-10-27
EA199800946A1 (ru) 1999-06-24
DE69735295D1 (de) 2006-04-27
TR199802423T2 (xx) 1999-02-22
ID16966A (id) 1997-11-27
AU2958997A (en) 1998-01-05
CO4850562A1 (es) 1999-10-26
PL330111A1 (en) 1999-04-26
YU53098A (sh) 2000-03-21
GB9610992D0 (en) 1996-07-31
KR20000015935A (ko) 2000-03-15
EA001860B1 (ru) 2001-10-22
IS4892A (is) 1998-11-10
DE69735295T2 (de) 2006-10-05
CN1219882A (zh) 1999-06-16
ATE318146T1 (de) 2006-03-15
PE69098A1 (es) 1998-12-02
ES2258277T3 (es) 2006-08-16
EP0907378B1 (en) 2006-02-22
CA2254983A1 (en) 1997-12-04
EP0907378A1 (en) 1999-04-14
IL126940A0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
NO985464L (no) Konsentrert antistoffpreparat
NO2009028I1 (no) Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasøytisk preparat
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
DK0870003T4 (da) Hydrobehandlingskatalysator: sammensætning, fremstilling og anvendelse deraf
NO965103L (no) Bicykliske aromatiske forbindelser, anvendelse derav, og farmasöytiske og kosmetiske preparater
NO974572D0 (no) Cyklodextrin-forbindelser, fremgangsmåter for fremstilling og anvendelse derav
DK0826673T3 (da) Acetamidderivater, fremgangsmåde til fremstilling deraf og medicinske præparater
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
NO308854B1 (no) Terapeutiske forbindelser, farmasøytisk akseptable salter og formuleringer inneholdende forbindelsene, samt anvendelser derav
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
DE69828895D1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
ITRM920412A1 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiego terapeutico.
NO880434D0 (no) Anestetisk preparat og fremgangsmaate for bruk derav.
NO307510B1 (no) Bicykliske aromatiske forbindelser, deres anvendelse og farmasøytiske og kosmetiske preparater derav
NO975020D0 (no) Azacykloalkanderivater, fremstilling derav og deres anvendelse i terapi
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
NO891006D0 (no) Terapeutisk aktivt polypeptid og fremgangsmaate for dets fremstilling.
NO962477L (no) Benzamidderivater, deres fremstilling og deres terapautiske anvendelse
NO931342D0 (no) Benzimidazoler, medisinske preparater inneholdende disse,og fremgangsmaate for deres fremstilling
NO973980D0 (no) Imiadazolderivater og medisinsk preparat
NO326826B1 (no) Alfa-aminosyreamider, fremstilling og terapeutisk anvendelse derav
DK0835254T3 (da) Oxazolidinonderivater, deres fremstilling og deres terapeutiske anvendelse
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application